Global veterinary health group Ceva has invested EUR18 million (US$22.6 million) in renovating and extending its sterile products plant in Libourne, France. The new industrial facility was inaugurated October 3 and will increase injectable drug production capacity.
Driving innovation is the key factor behind Ceva’s pharmaceutical strategy and to meet the demand of future growth, Ceva invested in expanding and improving the controlled-atmosphere production areas at its Libourne plant. After two and a half years of work without shutting down existing production facilities, an extension of 500 square meters has now been completed, along with the renovation of 1,000 square meters of new existing floor areas and installation of new manufacturing and filling equipment.
“This project was an essential step to support our ambitions and secure the plant’s competitive edge. Eighteen million 100ml vials can be produced by the plant each year, and the first order for China will be leaving next week,” said Emmanuel Coudre, Libourne site director. “This new, high-performance industrial facility uses modern technologies in a state-of-the-art environment to comply with the highest international standards of good manufacturing practice and provide optimal working conditions for production personnel.”
This plant for the future has been designed to allow Ceva the possibility of making further developments in line with changes in product demand and pharmaceutical regulations.
